Danish diabetes-tech company Hedia has announced the appointment of Rasmus Kofoed as its new CEO.
Kofoed’s background in the life science and medical technology industries includes previous senior roles at companies such as Novo Nordisk, Abbott, Roche and Medtronic. He was also previously CEO and President of ChemoMetec, where his commercial and strategic responsibilities included the company’s growth, transformation and international expansion.
Hedia specialises in the development of a digital therapeutic (DTx) solution that helps those with diabetes self-manage their condition. Kofoed brings expertise in this field, having led diabetes-specific units at both Roche and Medtronic.
As CEO, Kofoed’s ambition is to build on Hedia’s product and market platform, as well as expanding its international partnerships. “I see enormous potential in Hedia,” Kofoed said. “The company combines clinical insight with technology in a way that creates real value for people with diabetes.”
Carl Bilbo, Chairman of the Board at Hedia, said: “We are pleased to welcome Rasmus Kofoed as our new CEO. [He] brings a strong strategic and commercial profile with proven experience in life science and medtech.”
Kofoed succeeds previous CEO Lars Christian Lund.